WaveMan
WaveMan · Company
ETST · Earth Science Tech, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ETST Earth Science Tech (ETST) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001538495
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Earth Science Tech insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Earth Science Tech, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Saumat Giorgio R.
CEO
BUY
2025-07-22 SEC
50,000
$10.5K
-52.7%
Context
  • 141 earlier Form 4 trades (code P or S) here by this insider (141 buys), the last on Jul 21, 2025.
  • +9.2% median (+67.1% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 122,930,127 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: CEO Saumat Giorgio R. bought about $10.5K of ETST on Jul 22, 2025; 1 other insider bought within 30 days.
Saumat Giorgio R.
CEO
BUY
2025-07-21 SEC
100,000
$20.0K
-52.7%
Context
  • 140 earlier Form 4 trades (code P or S) here by this insider (140 buys), the last on Feb 24, 2025.
  • +9.2% median (+67.2% mean) 90-day return after 30 previous buys.
  • The trade is 0.1% of the 122,880,127 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: CEO Saumat Giorgio R. bought about $20.0K of ETST on Jul 21, 2025; 1 other insider bought within 30 days.
Sanchez Yovan Arturo
Director
BUY
2025-07-09 SEC
131
$24
-46.5%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 buys), the last on Jul 8, 2025.
  • +8.7% median (+48.0% mean) 90-day return after 24 previous buys.
  • The trade is 0.0% of the 1,678,192 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: Director Sanchez Yovan Arturo bought about $24 of ETST on Jul 9, 2025; 1 other insider bought within 30 days.
Sanchez Yovan Arturo
Director
BUY
2025-07-09 SEC
20,459
$3.7K
-46.5%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 buys), the last on Jul 8, 2025.
  • +8.7% median (+48.0% mean) 90-day return after 24 previous buys.
  • The trade is 1.2% of the 1,698,651 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: Director Sanchez Yovan Arturo bought about $3.7K of ETST on Jul 9, 2025; 1 other insider bought within 30 days.
Sanchez Yovan Arturo
Director
BUY
2025-07-09 SEC
1,349
$243
-46.5%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 buys), the last on Jul 8, 2025.
  • +8.7% median (+48.0% mean) 90-day return after 24 previous buys.
  • The trade is 0.1% of the 1,700,000 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: Director Sanchez Yovan Arturo bought about $243 of ETST on Jul 9, 2025; 1 other insider bought within 30 days.
191 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 186 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+7.8% year over year
more than 57% of Pharma & Biotech
Margin
10.2% net margin
more than 81% of Pharma & Biotech
Buybacks
$392.2K repurchased, FY to 2026-06-30
below 91% of Pharma & Biotech
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
the lowest in Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ETST

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-46.9%12M
-54%-25%+4%+33%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ETST: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in ETST

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ETST planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ETST financials

Revenue growth
+7.8%
XBRL, annual
Net margin
10.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$36.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+10.8%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$1.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.03x
long-term 2024-12-31 (18 months older than the period end) plus current 2025-03-31 (15 months older than the period end); equity 2026-06-30
Cash flow to debt
10.39x
TTM operating cash flow over long-term 2024-12-31 (18 months older than the period end) plus current 2025-03-31 (15 months older than the period end)
Return on equity
+66.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+42.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
7.28x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$26.8M
market value at close 2026-10-26 on 2026-08-06 shares, plus long-term 2024-12-31 (18 months older than the period end) plus current 2025-03-31 (15 months older than the period end), minus cash 2026-06-30
FCF yield
+6.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
0.16x
P/E over trailing EPS growth of 44%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-032025-032024-032023-03
Revenue$35.7M$33.1M$12.0M$48.5K
Gross profit$25.5M$24.3M$7.8M$22.1K
Operating incomen/an/a$892.3K-$936.7K
Net income$3.6M$3.3M$812.1K-$365.4K
EPS (diluted)0.010.010.00-0.00
Operating cash flow$1.9M$4.4M$1.2M-$1.0M
Cash$796.8K$1.5Mn/a$35.8K
Long-term debtn/an/a$60.6K$204.4K
Buybacks$471.4K$1.5M$178.0Kn/a
SEC XBRL, fiscal years, as known on 2026-10-28

ETST Stock Sonar score 4/7 axes

Find similar shapesCompare

ETST ranks highest on profitability (95th percentile) and financial health (83rd), and lowest on growth (57th), among Pharma & Biotech peers.

Profitability
95
Inputs
  • Return on equity+66.9% · 95 pct, sector of 545
  • Return on assets+42.9% · 96 pct, sector of 691
  • Return on invested capitalfewer than four consecutive quarters of operating income
  • Return on capital employedfewer than four consecutive quarters of operating income
Financial health
83
Inputs
  • Debt to equity0.03x · 68 pct, sector of 352
  • Cash flow to debt10.39x · 97 pct, sector of 371
Growth
57
Inputs
  • Revenue growth, YoY+7.8% · 57 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
68
Inputs
  • Short interest, % of float+0.0% · 100 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+13.3% · 36 pct, sector of 511
3 not measured: Insider conviction, Institutional and government, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies